BD Medical has obtained 510(k) approval from the US Food and Drug Administration (FDA) for its new insulin infusion set with FlowSmart technology.
Insulin infusion set is said to connect the insulin pump to the body.
BD collaborated with JDRF and The Leona M. and Harry B. Helmsley Charitable Trust on the research and development of the new infusion set, in a bid to enhance the performance of insulin pumps and improve the treatment of type 1 diabetes.
BD Medical-Diabetes Care worldwide president Kenneth Miller said: "We believe that our new infusion set with BD FlowSmart technology is a ground-breaking innovation in diabetes technology that redefines the role of infusion sets in pump therapy by reducing the incidence of silent occlusions.
"We are especially pleased to achieve this milestone in collaboration with JDRF and the Helmsley Charitable Trust, and that our work together may help people better control their diabetes."
BD FlowSmart features an advanced side-ported catheter, designed to enhance insulin flow and reduce the number of flow interruptions.
The infusion set also comprises smallest insertion needle, which has been developed to reduce insertion pain and trauma.
BD plans to introduce the new product in the US in fiscal year 2016.
The infusion set with BD FlowSmart technology also obtained approval for sale in Canada, and an application was submitted for CE mark approval.